Sign inJoin waitlistJoin the waitlist

Natalie Grover

Medical Oncology · Unc Physicians and Associates

Credentials: · · ·

History

Research

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Journal of Clinical Oncology · 2020 · 318 citations
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Blood · 2022 · 81 citations
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
Journal of Clinical Oncology · 2023 · 78 citations

Narendranath Epperla
28 papers
Reem Karmali
24 papers
SB
Stefan Barta
20 papers
Jonathon Cohen
19 papers
Anne Beaven
14 papers
Brian Hill
14 papers
Christopher Dittus
14 papers
Steven Park
14 papers
AD
Alexey Danilov
13 papers
Geoffrey Shouse
13 papers
Nilanjan Ghosh
13 papers
BK
Brad Kahl
12 papers

Clinical trials

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
Principal investigator · Withdrawn · Phase 1, Phase 2
UNC Lineberger Comprehensive Cancer Center
2025
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
Principal investigator · Recruiting · Phase 1, Phase 2
UNC Lineberger Comprehensive Cancer Center
2024–2033
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Principal investigator · Recruiting · Phase 1
UNC Lineberger Comprehensive Cancer Center
2020–2043
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Principal investigator · Active not recruiting · Early phase 1
UNC Lineberger Comprehensive Cancer Center
2019–2037